A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Purpose

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

Condition

  • Relapsed or Refractory Multiple Myeloma

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:. i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or. ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,. iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio. - Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, [with or without] hematopoietic stem cell transplant, (with or without) consolidation, and/or [with or without] maintenance therapy). - Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible). - Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy. - Participant must have documented disease progression during or after their last antimyeloma regimen.

Exclusion Criteria

  • Participant who has had prior treatment with mezigdomide or carfilzomib. - Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment. - Other protocol-defined Inclusion/Exclusion criteria apply.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
This is a two-stage inferentially seamless design.
Primary Purpose
Treatment
Masking
None (Open Label)
Masking Description
This is an open-label study; however, any review of aggregate study data by the Sponsor will be performed in a blinded manner.

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)
  • Drug: Mezigdomide
    Specified dose on specified days
    Other names:
    • BMS-986348
    • CC-92480
  • Drug: Carfilzomib
    Specified dose on specified days
    Other names:
    • Kyprolis
  • Drug: Dexamethasone
    Specified dose on specified days
    Other names:
    • Decadron
    • Dex
Active Comparator
Kd (Carfilzomib + Dexamethasone)
  • Drug: Carfilzomib
    Specified dose on specified days
    Other names:
    • Kyprolis
  • Drug: Dexamethasone
    Specified dose on specified days
    Other names:
    • Decadron
    • Dex

Recruiting Locations

USA Mitchell Cancer Institute
Mobile, Alabama 36604
Contact:
Omar Alkharabsheh, Site 0046
251-665-8000

TOI Clinical Research
Cerritos, California 90703
Contact:
Amitabha Mazumder, Site 0005
562-693-4477

Kaiser Permanente - Irvine
Irvine, California 92618
Contact:
Ashraf Aziz, Site 0190
800-398-3996

Los Angeles Hematology Oncology Medical Group
Los Angeles, California 90017
Contact:
Lasika Seneviratne, Site 0187
626-627-6666

Sutter Santa Rosa
Santa Rosa, California 95403
Contact:
Zeyad Kanaan, Site 0344
707-521-7750

Stockton Hematology Oncology Group
Stockton, California 95204
Contact:
Neelesh Bangalore, Site 0339
209-466-2626

Florida Cancer Specialists - South
Fort Myers, Florida 33901
Contact:
Syed Zafar, Site 0341
239-274-9930

Florida Cancer Specialists - North
Saint Petersburg, Florida 33705
Contact:
Gustavo Fonseca, Site 0342
000-000-0000

Florida Cancer Specialists - East
West Palm Beach, Florida 33401
Contact:
Shachar Peles, Site 0340
561-366-4100

Emory University School of Medicine- Grady Campus
Atlanta, Georgia 30303
Contact:
Nisha Joseph, Site 0348
502-608-5503

Winship Cancer Institute, Emory University
Atlanta, Georgia 30322
Contact:
Nisha Joseph, Site 0291
502-608-5503

Anne Arundel Medical Center
Annapolis, Maryland 21401
Contact:
Imad Tabbara, Site 0289
703-217-1760

Dana-Farber Cancer Institute
Boston, Massachusetts 02215
Contact:
Monique Hartley-Brown, Site 0204
857-299-5736

Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota 55404
Contact:
Sandeep Jain, Site 0346
952-892-7190

Regional Cancer Care Associates
Little Silver, New Jersey 07739
Contact:
iuliana Shapira, Site 0222
732-530-8666

Montefiore Medical Center
Bronx, New York 10467
Contact:
Ridhi Gupta, Site 0199
718-920-4826

University Hospitals Cleveland Medical Center
Cleveland, Ohio 44106
Contact:
James Ignatz-Hoover, Site 0322
440-897-3232

Riverside Methodist Hospital
Columbus, Ohio 43214
Contact:
Yvonne Efebera, Site 0172
216-965-8569

Lifespan Cancer Institute
Providence, Rhode Island 02903
Contact:
Rabin Niroula, Site 0321
401-444-3000

Gibbs Cancer Center & Research Institute
Greer, South Carolina 29650
Contact:
Tondre Buck, Site 0338
864-560-7050

Tennessee Oncology Chattanooga
Chattanooga, Tennessee 37404
Contact:
Jesus Berdeja, Site 0349
615-329-0570

Tennessee Oncology
Nashville, Tennessee 37203
Contact:
Jesus Berdeja, Site 0323
615-329-0570

John Peter Smith Hospital
Fort Worth, Texas 76104
Contact:
Kalyani Narra, Site 0337
817-702-8049

Kelsey-Seybold Clinic
Houston, Texas 77025
Contact:
Tri Vu, Site 0328
713-442-1223

Houston Methodist Hospital
Houston, Texas 77030
Contact:
Carrie Yuen, Site 0044
832-571-7244

Virginia Oncology Associates
Norfolk, Virginia 23502
Contact:
David Kobulnicky, Site 0345

Blue Ridge Cancer Care
Roanoke, Virginia 24014
Contact:
Amanda Gillespie-Twardy, Site 0343
540-982-0237

Northwest Medical Specialties PLLC
Tacoma, Washington 98405
Contact:
Francis Senecal, Site 0006
253-428-8700

Northwest Cancer Specialists, P.C.
Vancouver, Washington 98684
Contact:
Tristan Bice, Site 0347
360-944-9889

WVU Cancer Institute
Morgantown, West Virginia 26506
Contact:
Salah ud din Safi, Site 0243
304-598-6984

Marshfield Medical Center - Marshfield
Marshfield, Wisconsin 54449
Contact:
Isaac Yeboah, Site 0336
715-387-5416

Pan American Center for Oncology Trials - Ciudadela
San Juan, Puerto Rico 00909
Contact:
Maria Garcia-Pallas, Site 0316
7874073333

More Details

NCT ID
NCT05552976
Status
Recruiting
Sponsor
Bristol-Myers Squibb

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
Clinical.Trials@bms.com

For help using this page: trialstoday@researchmatch.org or call 855-514-7001

ResearchMatch is funded in part by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, led by the NIH’s National Center for Advancing Translational Sciences (NCATS), grants UL1TR000445 and 1U54RR032646-01, and grant U24TR001579 from NCATS and the National Library of Medicine. The content of this website is solely the responsibility of ResearchMatch and Vanderbilt University and does not necessarily represent the official views of the NIH, NCATS, or NLM.

Vanderbilt University Medical Center